Pulmonary embolism (PE) remains a significant cause of cardiovascular-related morbidity and mortality, with disparities in management and outcomes affecting various demographic groups. The American Heart Association’s scientific statement reveals that Black and Hispanic individuals, reproductive-age women, and transgender people taking estrogen hormones face higher incidences of PE. These disparities are compounded by socioeconomic factors, which correlate with poorer outcomes, including recurrent PE, chronic thromboembolic pulmonary hypertension, and increased mortality rates.
Race, ethnicity, sex, and socioeconomic status influence the clinical presentation, diagnosis, and treatment of PE. For example, Black and Hispanic patients often experience delays in diagnosis and treatment, leading to worse outcomes. The statement calls for equitable PE care and emphasizes the need for policy-level interventions to address these disparities.
Personal stories within the statement illustrate the human impact of these inequities. One narrative describes a Black patient who struggled with recurrent PE due to delayed diagnosis, underscoring the urgent need for systemic change. The statement advocates for inclusive policies and better support systems to ensure all patients receive timely and effective care.
Addressing these disparities requires a multifaceted approach, including policy reform, community outreach, and increased funding for minority health programs. By recognizing and tackling these inequities, the healthcare system can improve outcomes for those most affected by PE.
See: “Disparities in Current Pulmonary Embolism Management and Outcomes” (March 20, 2025)
